128 related articles for article (PubMed ID: 38761480)
41. Sphingolipid, fatty acid and phospholipid metabolites are associated with disease severity and mTOR inhibition in lymphangioleiomyomatosis.
Bottolo L; Miller S; Johnson SR
Thorax; 2020 Aug; 75(8):679-688. PubMed ID: 32467337
[TBL] [Abstract][Full Text] [Related]
42. Effects of sirolimus in lymphangioleiomyomatosis patients on lung cysts and pulmonary function: long-term follow-up observational study.
Kim C; Do KH; Cha J; Song JW; Lee SM; Lee KY
Eur Radiol; 2020 Feb; 30(2):735-743. PubMed ID: 31471750
[TBL] [Abstract][Full Text] [Related]
43. Characterization of cells cultured from chylous effusion from a patient with sporadic lymphangioleiomyomatosis.
Grzegorek I; Zuba-Surma E; Chabowski M; Janczak D; Szuba A; Dziegiel P
Anticancer Res; 2015 Jun; 35(6):3341-51. PubMed ID: 26026094
[TBL] [Abstract][Full Text] [Related]
44. [Lymphangioleiomyomatosis].
Wirtz H
Zentralbl Chir; 2013 Oct; 138 Suppl 1():S59-74; quiz 75-6. PubMed ID: 24277558
[TBL] [Abstract][Full Text] [Related]
45. [Lymphedema in patients treated with sirolimus: 15 cases].
Fourgeaud C; Simon L; Benoughidane B; Vignes S
Rev Med Interne; 2019 Mar; 40(3):151-157. PubMed ID: 29752013
[TBL] [Abstract][Full Text] [Related]
46. Efficacy and safety of low-dose Sirolimus in Lymphangioleiomyomatosis.
Yoon HY; Hwang JJ; Kim DS; Song JW
Orphanet J Rare Dis; 2018 Nov; 13(1):204. PubMed ID: 30428897
[TBL] [Abstract][Full Text] [Related]
47. High Incidence of Ovarian Cysts in Women Receiving mTOR Inhibitors After Renal Transplantation.
Bachmann F; Glander P; Budde K; Bachmann C
J Womens Health (Larchmt); 2018 Mar; 27(3):394-398. PubMed ID: 29087803
[TBL] [Abstract][Full Text] [Related]
48. Sirolimus treatment for recurrent lymphangioleiomyomatosis after lung transplantation.
Chen F; Omasa M; Kondo N; Fujinaga T; Shoji T; Sakai H; Bando T
Ann Thorac Surg; 2009 Jan; 87(1):e6-7. PubMed ID: 19101258
[TBL] [Abstract][Full Text] [Related]
49. Reduction in size of renal angiomyolipoma after treatment with everolimus in lung transplantation due to lymphangioleiomyomatosis.
Bujalance-Cabrera C; Vaquero-Barrios JM; Redel-Montero J; Caballero-Ballesteros L; Requejo-Jiménez A; Santos-Luna F
Arch Bronconeumol; 2012 Dec; 48(12):479-81. PubMed ID: 22444789
[TBL] [Abstract][Full Text] [Related]
50. Retrospective review of combined sirolimus and simvastatin therapy in lymphangioleiomyomatosis.
Taveira-DaSilva AM; Jones AM; Julien-Williams PA; Stylianou M; Moss J
Chest; 2015 Jan; 147(1):180-187. PubMed ID: 25167325
[TBL] [Abstract][Full Text] [Related]
51. Improving Survival in Lymphangioleio-myomatosis: A 16-Year Observational Study in a Large Cohort of Patients.
Harari S; Torre O; Elia D; Caminati A; Pelosi G; Specchia C; Zompatori M; Cassandro R
Respiration; 2021; 100(10):989-999. PubMed ID: 34044410
[TBL] [Abstract][Full Text] [Related]
52. Connectivity Map Analysis of a Single-Cell RNA-Sequencing -Derived Transcriptional Signature of mTOR Signaling.
Al Mahi N; Zhang EY; Sherman S; Yu JJ; Medvedovic M
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922083
[TBL] [Abstract][Full Text] [Related]
53. Increased Mortality in Adult Cystic Fibrosis Patients with Medicaid Insurance Awaiting Lung Transplantation.
Krivchenia K; Tumin D; Tobias JD; Hayes D
Lung; 2016 Oct; 194(5):799-806. PubMed ID: 27510183
[TBL] [Abstract][Full Text] [Related]
54. Lymphangioleiomyomatosis: New Treatment Perspectives.
Radzikowska E
Lung; 2015 Aug; 193(4):467-75. PubMed ID: 25980593
[TBL] [Abstract][Full Text] [Related]
55. An Intention-to-treat View of Lung Transplantation for Interstitial Lung Disease: Successful Strategies to Minimize Waiting List and Posttransplant Mortality.
Zhu MZL; Levvey BJ; McGiffin DC; Snell GI
Transplantation; 2022 Jan; 106(1):188-199. PubMed ID: 33988345
[TBL] [Abstract][Full Text] [Related]
56. Lung and heart-lung transplantation for children with PAH: Dramatic benefits from the implementation of a high-priority allocation program in France.
Le Pavec J; Feuillet S; Mercier O; Pauline P; Dauriat G; Crutu A; Florea V; Savale L; Levy M; Laverdure F; Stephan F; Fabre D; Delphine M; Boulate D; Mussot S; Hascoët S; Bonnet D; Humbert M; Fadel E
J Heart Lung Transplant; 2021 Jul; 40(7):652-661. PubMed ID: 33849770
[TBL] [Abstract][Full Text] [Related]
57. Long-term stable lung function and second uncomplicated pregnancy on sirolimus in lymphangioleiomyomatosis (LAM).
Faehling M; Wienhausen-Wilke V; Fallscheer S; Trinajstic-Schulz B; Weber J; Leschke M
Sarcoidosis Vasc Diffuse Lung Dis; 2015 Sep; 32(3):259-64. PubMed ID: 26422572
[TBL] [Abstract][Full Text] [Related]
58. Lung transplantation for lymphangioleiomyomatosis: role of imaging in the assessment of complications related to the underlying disease.
Collins J; Müller NL; Kazerooni EA; McAdams HP; Leung AN; Love RB
Radiology; 1999 Feb; 210(2):325-32. PubMed ID: 10207410
[TBL] [Abstract][Full Text] [Related]
59. Long-term results of sirolimus treatment in lymphangioleiomyomatosis: a single referral centre experience.
Revilla-López E; Berastegui C; Méndez A; Sáez-Giménez B; Ruiz de Miguel V; López-Meseguer M; Monforte V; Bravo C; Pujana MA; Ramon MA; Gómez-Ollés S; Roman A;
Sci Rep; 2021 May; 11(1):10171. PubMed ID: 33986388
[TBL] [Abstract][Full Text] [Related]
60. Multi-dimensional scores to predict mortality in patients with idiopathic pulmonary fibrosis undergoing lung transplantation assessment.
Fisher JH; Al-Hejaili F; Kandel S; Hirji A; Shapera S; Mura M
Respir Med; 2017 Apr; 125():65-71. PubMed ID: 28340864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
